Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Xerostomia Therapeutics Market Size, Value And Growth Trends Through 2030
The xerostomia therapeutics market has experienced consistent growth over the past several years. Projected figures indicate an expansion from $2.24 billion in 2025 to $2.35 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.0%. This upward trend during the historical period has been driven by factors such as an aging demographic, the extensive use of medications that induce dry mouth, a growing incidence of chronic health conditions, heightened awareness of dental health, and the management of symptoms within hospital settings.
The xerostomia therapeutics market is projected to experience consistent expansion over the coming years. By 2030, it is anticipated to reach $2.79 billion, registering a compound annual growth rate (CAGR) of 4.3%. This anticipated growth during the forecast period is driven by factors such as the increased availability of over-the-counter products, a rise in side effects linked to cancer therapies, a growing tendency toward self-medication, the broadening of pharmacy networks, and an enhanced emphasis on treatments that improve quality of life. Key trends shaping this period include a higher incidence of dry mouth caused by medications, a growing preference for over-the-counter remedies, a wider adoption of artificial saliva solutions, the expansion of both retail and mail-order pharmacy services, and a stronger focus on managing oral symptoms.
Download A Free Sample Report For Comprehensive Market Insights:
Xerostomia Therapeutics Market Development Factors: Which Trends Are Supporting Demand?
The increasing occurrence of chronic illnesses is anticipated to boost the expansion of the xerostomia therapeutics market in the upcoming period. Chronic illnesses are long-term medical conditions that last for months or years, often developing gradually and demanding continuous care. Their rising frequency is largely attributed to inactive lifestyles, since insufficient regular physical activity leads to obesity, heart disease, diabetes, and other persistent health issues. Xerostomia therapeutics assist in managing chronic diseases by relieving dry mouth symptoms and enhancing oral health, dietary intake, and medication compliance—essential aspects for controlling long-term conditions. For example, in June 2024, data from the National Health Service, a UK governmental organization, showed that 3,615,330 individuals registered with a general practitioner (GP) had non-diabetic hyperglycemia or pre-diabetes in 2023, an 18% rise from 3,065,825 cases in 2022. Consequently, the growing prevalence of chronic diseases is fueling the advancement of the xerostomia therapeutics market.
Xerostomia Therapeutics Market Driver: Growing Geriatric Population Boosting Demand Due to Higher Dry-Mouth Risk
The expanding elderly population is set to drive the growth of the xerostomia therapeutics market in the future. The term geriatric population describes the increasing number of individuals aged 65 and older worldwide. This demographic shift is fueled by falling birth rates and longer life expectancies globally. The xerostomia therapeutics sector aids older adults by offering saliva-stimulating products and oral moisturizers that alleviate dry mouth, facilitating easier chewing, swallowing, and proper nutrition. As an illustration, in July 2024, the House of Commons Library within the UK Parliament reported that in 2022, 12.7 million people in the UK were 65 or older—19% of the total population—with projections indicating a rise to 22.1 million by 2072, making up 27% of the population. Thus, the aging population is propelling the expansion of the xerostomia therapeutics market.
Xerostomia Therapeutics Market Segment Outlook: Which Categories Are Expanding The Fastest?
The xerostomia therapeutics market covered in this report is segmented –
1) By Type: Artificial Saliva Or Saliva Substitutes, Salivary Stimulants
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Mail Order Pharmacies, Hypermarkets And Supermarkets
3) By End-User: Adult, Pediatric
Subsegments:
1) By Artificial Saliva Or Saliva Substitutes: Oral Sprays, Gels, Lozenges, Mouthwashes
2) By Salivary Stimulants: Prescription Drugs, Over-The-Counter (Otc) Products, Chewing Gums And Lozenges
Xerostomia Therapeutics Market Transformation Trends: Which Innovations Are Driving Change?
Leading players in the xerostomia therapeutics space are increasingly prioritizing non-invasive, patient-friendly solutions like oral sprays, which deliver targeted topical lubrication and create a protective barrier throughout the mouth to alleviate dry-mouth symptoms while promoting better oral health. These oral sprays for xerostomia are formulated as a fine mist applied directly to oral tissues, including the tongue, palate, and inner cheeks, where they establish either a hydrating film or a lipid-based coating that curbs moisture loss, improves lubrication during eating, swallowing, and speaking, and provides extended relief for individuals experiencing chronic dry mouth. As a case in point, in July 2023, K Pharmaceuticals, a US-based pharmaceutical company, introduced Aquoral, a clinically validated oral spray designed to manage xerostomia. This product utilizes patented Oxidized Glycerol Triesters (OGT) lipid technology to produce a durable protective shield over the oral cavity, delivering up to six hours of symptom relief with just two quick sprays, thereby minimizing the frequency of reapplication when compared to water-based alternatives.
Xerostomia Therapeutics Market Key Companies And Competitive Benchmarking
Major companies operating in the xerostomia therapeutics market are GlaxoSmithKline plc, Colgate-Palmolive Company, Sun Pharmaceutical Industries Ltd., Cipla Ltd., Synedgen Inc., Mission Pharmacal Company, Dentaid Ltd., Sunstar Suisse S.A., Forward Science Holding Inc., OraCoat, Oralieve UK Ltd., OraPharma Inc., OraVital Inc., Saliwell Limited, Bayer AG, 3M Company, Church & Dwight Co. Inc., Hikma Pharmaceuticals PLC, Lupin Limited, Teva Pharmaceutical Industries Ltd.
Access The Complete Xerostomia Therapeutics Market Report:
Xerostomia Therapeutics Market Regional Analysis And Leading Geography
North America was the largest region in the xerostomia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the xerostomia therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model